**Name of Journal:** *World Journal of Critical Care Medicine*

**Manuscript NO:** 67269

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital**

Iglesias JI *et al*. Retrospective analysis of therapies for COVID-19

Jose I Iglesias, Andrew V Vassallo, Jesse B Sullivan, Yasmine Elbaga, Vishal V Patel, Nikunjkumar Patel, Lydia Ayad, Payam Benson, Marina Pittiglio, Emad Gobran, Alexander Clark, Wajahat Khan, Kaliope Damalas, Rajesh Mohan, Satyendra P Singh

**Jose I Iglesias, Wajahat Khan,** Department of Critical Care, Community Medical Center, Toms River, NJ 08757, United States

**Jose I Iglesias,** Department of Nephrology, Community Medical Center, Toms River, NJ 08757, United States

**Jose I Iglesias,** Department of Nephrology, Jersey Shore University Medical Center, Hackensack Meridian School of Medicine at Seton Hall, Neptune, NJ 07753, United States

**Andrew V Vassallo, Vishal V Patel, Marina Pittiglio, Kaliope Damalas,** Department of Pharmacy, Community Medical Center, Toms River, NJ 08757, United States

**Jesse B Sullivan,** Fairleigh Dickinson University School of Pharmacy & Health Sciences, Fairleigh Dickinson University, Florham Park, NJ 07932, United States

**Yasmine Elbaga, Alexander Clark,** Department of Pharmancy, Monmouth Medical Center Southern Campus, Lakewood, NJ 08701, United States

**Nikunjkumar Patel, Lydia Ayad, Payam Benson, Emad Gobran,** Department of Medicine, Community Medical Center, Toms River, NJ 08757, United States

**Rajesh Mohan,** Department of Cardiology, Monmouth Medical Center Southern Campus, Lakewood, NJ 08701, United States

**Satyendra P Singh,** Department of Medicine, Monmouth Medical Center Southern Campus, Lakewood, NJ 08701, United States

**Author contributions:** Iglesias JI and Vassallo AV contributed to conceptualization, methodology, and formal analysis; Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y and Patel VV wrote the original draft; Data collection along with manuscript review and editing was performed by Iglesias JI, Vassallo AV, Elbaga Y, Patel N, Gobran E, Ayad L, Pittiglio M, Khan W, Benson P, Damalas K, Clark A, Singh SP, and Mohan R.

**Corresponding author: Jose I Iglesias, DO, Associate Professor,** Department of Critical Care, Community Medical Center, 99 W Rt 37, Toms River, NJ 08757, United States. jiglesias23@gmail.com

**Received:** April 21, 2021

**Revised:** June 23, 2021

**Accepted:** August 4, 2021

**Published online:** September 9, 2021

**Abstract**

BACKGROUND

Our understanding of the severe acute respiratory syndrome coronavirus 2 has evolved since the first reported cases in December 2019, and a greater emphasis has been placed on the hyper-inflammatory response in severely ill patients. The purpose of this study was to determine risk factors for mortality and the impact of anti-inflammatory therapies on survival.

AIM

To determine the impact of various therapies on outcomes in severe coronavirus disease 2019 patients with a focus on anti-inflammatory and immune-modulating agents.

METHODS

A retrospective analysis was conducted on 261 patients admitted or transferred to the intensive care unit in two community hospitals between March 12, 2020 and June 17, 2020. Totally 167 patients received glucocorticoid (GC) therapy. Seventy-three patients received GC alone, 94 received GC and tocilizumab, 28 received tocilizumab monotherapy, and 66 received no anti-inflammatory therapy.

RESULTS

Patient survival was associated with GC use, either alone or with tocilizumab, and decreased vasopressor requirements. Delayed administration of GC was found to decrease the survival benefit of GC therapy. No difference in survival was found with varying anticoagulant doses, convalescent plasma, tocilizumab monotherapy~~;~~ prone ventilation, hydroxychloroquine, azithromycin, or intravenous ascorbic acid use.

CONCLUSION

This analysis demonstrated the survival benefit associated with anti-inflammatory therapy of GC, with or without tocilizumab, with the combination providing the most benefit. More studies are needed to assess the optimal timing of anti-inflammatory therapy initiation.

**Key Words:** COVID-19; Corticosteroids; Intensive care unit; Methylprednisolone; Tociluzimab; Anti-inflammatory

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Iglesias JI, Vassallo AV, Sullivan JB, Elbaga Y, Patel VV, Patel N, Ayad L, Benson P, Pittiglio M, Gobran E, Clark A, Khan W, Damalas K, Mohan R, Singh SP. Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. *World J Crit Care Med* 2021; 10(5): 244-259

**URL:** https://www.wjgnet.com/2220-3141/full/v10/i5/244.htm

**DOI:** https://dx.doi.org/10.5492/wjccm.v10.i5.244

**Core Tip:** Anti-inflammatory therapy with glucocorticoids (including methylpredsnisolone) and combination treatment with tocilizumab and glucocorticoids improve survival in critically ill patients with coronavirus disease 2019. Dual inhibition of the NFK-β therapy with glucocorticoid and inhibition of the interleukin-6 pathway with tocilizumab may offer greater survival benefits.

**INTRODUCTION**

In late December 2019, patients in Wuhan, China began presenting to hospitals with a viral pneumonia of unknown origin characterized by a clinical syndrome comprising of cough and dyspnea[1,2]. While there was a wide range of severity, the disease could lead to respiratory failure and death. Caused by the coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this disease state was named the coronavirus disease 2019 (COVID-19). Following rapid international spread, the World Health Organization upgraded the outbreak to a pandemic, the first pandemic since the 2009 H1N1 outbreak[3]. As of January 29, 2021, the disease has over 100 million cases confirmed infections and over 2 million confirmed deaths[4]. Our understanding of the disease state has continued to evolve as well. While the high mortality rate was originally thought to be closely related to acute respiratory distress syndrome (ARDS), newer evidence has shown additional potential causes[5]. Severely ill patients may have a hyper immune response, leading to dysregulated and excessive cytokine release which can lead to multiple-organ failure[6]. Patients have been found to enter a hypercoagulable state, leading to increased risk of thrombosis and strokes[7,8]. Our better understanding and continued research has led to rapid changes in treatment recommendations for COVID-19.

Treatment for COVID-19 has been rapidly evolving as new evidence emerges. Therapies have focused on antivirals (*e.g.*, remdesivir, favipiravir), anti-inflammatory medications (dexamethasone, methylprednisolone), antibodies (convalescent plasma), immunotherapy (tocilizumab, anakinra, sarilumab), anticoagulation (heparin), vitamin therapy (ascorbic acid, vitamin D), different modalities of respiratory support, and other novel therapies (hydroxychloroquine, melatonin, famotidine)[9]. Remdesivir, an antiviral therapy, was the first approved therapy to treat COVID-19 in hospitalized patients aged 12 and older weighing at least 40 kg. Remdesivir shows in-vitro activity against SARS-CoV-2 as well as a quicker time to recovery in hospitalized COVID-19 patients[10-13].

Immune based therapies have theoretical benefits in the cytokine storm phase of the disease. Corticosteroids have been employed due to their potent anti-inflammatory and immunomodulatory effects. Dexamethasone showed favorable clinical results in COVID-19 in the RECOVERY trial, demonstrating a lower 28-d mortality in patients receiving invasive mechanical ventilation or oxygen alone[14]. Patients who did not require supplemental oxygen did not benefit from the addition of dexamethasone. A meta-analysis of 7 randomized controlled trials that included hydrocortisone, methylprednisolone, and dexamethasone showed lower 28-d all-cause mortality, however the majority of data came from the RECOVERY trial[15]. The METCOVID trial was a parallel, double-blind, placebo-controlled, randomized clinical trial which compared methylprednisolone *vs* placebo in hospitalized patients with COVID-19[16]. The primary endpoint of 28 d mortality was not different between groups, however a post-hoc analysis of the data demonstrated that patients > 60 years old who received methylprednisolone did have decreased 28 d mortality.

Some concerns remain over using corticosteroids to treat COVID-19. Data from other novel coronavirus infectious, namely Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) show a negative effect on virus clearance with steroid use[17,18]. Liu *et al*[19] showed negative effects of corticosteroids in COVID-19 including increased 28-d mortality and delayed viral clearance in a large multicenter retrospective analysis. Methylprednisolone made up the majority (96.8%) of the steroids used.

Tocilizumab is a monoclonal antibody which competitively inhibits the action of interleukin-6 (IL-6), a pro-inflammatory cytokine which correlates with disease severity in COVID-19[20,21]. Tocilizumab has shown mixed results in randomized clinical trials. Earlier trials used tocilizumab as mostly monotherapy with low utilization of corticosteroids and failed to show efficacy[22-25]. Later trials, such the REMAP CAP and RECOVERY trials, utilized corticosteroids in greater numbers due to the release of the RECOVERY trial data on dexamethasone, and showed decreased mortality with tocilizumab[26,27]. The RECOVERY trial included only patients with C-reactive protein (CRP) > 75 mg/L, while the REMAP CAP trial did not specify a CRP threshold for inclusion, but found the strongest effect in the subgroup with highest CRP.

**MATERIALS AND METHODS**

***Study population and data collection***

To determine risk factors for mortality and the impact of anti-inflammatory therapy on survival in patients critically ill from COVID-19 we conducted a retrospective analysis of 261 consecutive patients admitted or transferred to the intensive care unit (ICU) of two community hospitals from March 12th to June 17th 2020. The study was approved by the Community Medical Center Institutional Review Board (IRB # 20-005). Inclusion criteria were the following: confirmed diagnosis of SARS-CoV-2 (COVID-19) by a positive PCR test and signs and symptoms of COVID-19 infection, age greater than 18. The study baseline was the time of hospital admission. In terms of ICU management, patients received standard of care therapy. Management and timing of ventilator support, employment of ARDS net ventilator strategies, antibiotic use, anti-viral therapy, use of anticoagulation, initiation of vasopressors, use of convalescent plasma, glucocorticoid (GC) therapy (defined as GC use for greater than 48 h), and use of tocilizumab was determined by the ICU physician and consultants.

Patient demographics, comorbidities, clinical and outcome variables were obtained from the electronic medical record and entered into a de-identified database. Measurements included arterial blood gas, routine metabolic chemistries, CRP, D-Dimer, IL-6, ferritin, complete blood count with differential, and all variables necessary to calculate the Sequential Organ Failure Assessment (SOFA) score on admission. Other collected data included the day of admission, date of ICU transfer, date of death, length of vasopressor usage, days on mechanical ventilation, partial pressure of oxygen to fraction inspired of oxygen (PaO2/FIO2) ratio, time to initiation of GC therapy, time to ICU transfer, use of therapeutic agents [azithromycin, hydroxychloroquine, convalescent plasma, use of heparin (low molecular weight or unfractionated either as prophylaxis or full anticoagulant therapy), and use of tocilizumab].

Acute kidney injury (AKI) was deﬁned based on kidney disease: Improving Global Outcomes criteria; namely, an increase in serum creatinine (SCr) > 0.3 mg/dL or a level > 1.5 times the baseline value SCr by ≥ 0.3 mg/dL, within 48 h. Where SCr at baseline is unknown and there is no documented history of chronic kidney disease baseline SCr was arbitrarily assigned a value of 1 mg/dL[28]. Timing and indication for the initiation of renal replacement therapy were determined by the consulting nephrologist.

***Ethics statement***

All procedures performed in the study were in accordance with the 1964 Helsinki declaration and its later amendments. Patients’ data were kept confidential, and no patients’ identifiers were included in data files handled for the purposes of this study.

***Data analysis***

The major outcome evaluated was hospital survival for patients admitted or transferred to the ICU during the index admission. Employing Cox proportional hazards model we performed a risk factor analyses for in-hospital survival. Secondly, we evaluated the impact of anti-inflammatory therapy on patient survival.

Summary statistics were computed for the survivors, non-survivors, and treatment groups. Four treatment groups were evaluated: All patients who received GC therapy, GC therapy alone, tocilizumab + GC therapy, tocilizumab alone, and standard treatment alone (no anti-inflammatory therapy). The use of subcutaneous heparin (fractionated or unfractionated), use of convalescent plasma, azithromycin, hydroxychloroquine, antibiotic therapy, and vasopressor use were included as standard therapy. Due to our previous use of intravenous ascorbic acid (IVAA) in sepsis, IVAA use was evaluated as an adjunct treatment modality. We performed both univariate and multivariate analyses. Continuous variables were expressed as median with interquartile ranges, and compared by the Student’s *t*-test or the Wilcoxon rank-sum test as appropriate. Multiple comparisons were analyzed with Kruskal Wallis ANOVA or Bonferroni correction when indicated. Categorical values were compared with Pearson’s chi-squared test and Fisher’s exact test when indicated. Kaplan Meir survival curves with log-rank test analysis and Cox proportional hazards analysis were employed to compare factors associated with survival and to compare treatment groups. Variables that were significant by univariate analysis at *P* < 0.05 were candidates for multivariate analysis. Multivariate Cox proportional hazards with forward variable selection was performed to determine variables independently predictive of survival and for comparing anti-inflammatory therapy groups with standard care.

As there was the possibility of factors influencing the use of corticosteroids, a logistic regression analysis was implemented to create a propensity score for corticosteroid use. A propensity score was generated employing the following factors; age, sex, race, the diagnosis of chronic obstructive pulmonary disease (COPD), need for mechanical ventilation, and PaO2/FiO2 ratio on admission. Cox proportional hazards analysis with time to corticosteroid administration as a time-dependent covariate was employed to compare survival among groups. Survival analysis was performed with propensity score adjusted multivariate Cox proportional hazards analysis. Finally, we repeated Cox proportional hazards analysis with both propensity score adjustment and with time to corticosteroid administration as a time-dependent covariate.

**RESULTS**

***Patient characteristics***

From March 12, 2020 to June 17, 2020, 261 patients with COVID-19 were admitted to the ICU. There were 94 patients (36%) admitted directly to the ICU and 167 (64%) patients who were initially admitted to non-ICU COVID units then later transferred to ICU. During these four months, hospital mortality for ICU patients was 64% (167 patients). On univariate analysis, there was no significant difference in mortality between those directly admitted to ICU 59 (62%) *vs* transferred to ICU 108 (64%), (*P* = 0.74, odds ratio 0.92, 95% confidence interval 0.54-1.55). The median time to transfer to ICU was 3 d [interquartile range (IQR) 1-5]. In those patients not initially admitted to ICU, there was no statistically significant difference in time to ICU transfer between survivors and non-survivors median time 2 d (IQR 1-5) *vs* 3 d IQR (1-6) (*P* = 0.11). There was a statistically significant difference in SOFA scores in patients admitted to the ICU in comparison to those admitted to COVID-19 units [6 (IQR 3-10) *vs* 3.5 (IQR 2-5) *P* < 0.001]. The median age was 69 years (IQR 61-80), 60% of patients were greater than 65 years and 30% were older than 77, 129 patients (48%), were Caucasian and 158 (60%) were males. The majority of patients (*n* = 178, 68%) had or developed severe respiratory failure requiring mechanical ventilation, and 39 (15%) required hemodialysis. Of note 167 patients received corticosteroids; either hydrocortisone 100mg every 8 h (*n* = 12, 7%) or methylprednisolone 40mg every 12 h (*n* = 155, 92%). A total of 73 patients received GC alone, 94 received both tocilizumab and GC, 28 were on tocilizumab therapy alone, and 66 patients did not receive anti-inflammatory therapy. The dose of tocilizumab employed was 8 mg/kg.

***Univariate analysis: Predictors of survival and treatment***

Patient characteristics are described in Table 1. Univariate predictors of decreased survival included the need for mechanical ventilation, AKI, Caucasian race, male sex, older age, lower total lymphocyte count, higher neutrophil/lymphocyte ratio, and a greater degree of respiratory failure manifested by a lower PaO2/FIO2 ratio. Therapeutic and pharmacologic interventions are described in Table 2. Survival analysis employing univariate Cox proportional hazards analysis revealed patient survival was associated with use all patients receiving GC (GC alone and GC + tocilizumab), GC use alone, less use of vasopressors, and combination therapy with tocilizumab with GC (Table 3). It is pertinent to note that there was no statistically significant difference in survival with the use of anticoagulant doses of heparin, subcutaneous heparin, convalescent plasma, tocilizumab alone, prone ventilation, IVAA, hydroxychloroquine, or azithromycin use. All patients who received remdesivir expired (*n* = 6, 3%). As anticipated non-survivors demonstrated a higher degree of elevated inflammatory and pro-thrombotic markers interleukin-6 at 48 h, D-Dimer at 24 h and 48 h respectively (Table 4).

***Multivariate analysis/Cox proportional hazards analysis***

To identify independent predictors of survival, we performed multivariate Cox proportional hazards analysis with stepwise forward variable selection which revealed the following as independent predictors of decreased survival: increased age, male sex, and a requirement for vasopressors. GC use including those patients receiving GC alone and those receiving GC + tocilizumab was associated with survival (Table 5). Kaplan Meier survival analysis curves Kaplan Meier curve for GC treatment (GC alone and GC + tocilizimab) is represented in Figure 1 (GC use, log rank test *P* < 0.001).

As there was the possibility of factors influencing the use of GC, a logistic regression analysis was implemented to create a propensity score for GC use. A propensity score was generated employing the following factors; age, sex, race, the diagnosis of COPD, need for mechanical ventilation, and PaO2/FIO2 ratio on admission (Table 1 and Supplementary Figure 1). In order to confirm that anti-inflammatory therapy influenced survival we next repeated a propensity score adjusted Cox proportional hazards analysis with stepwise forward variable selection including GC alone, tocilizumab + GC, tocilizimab alone, and standard treatment. The model revealed independent predictors of decreased survival remained unchanged, conversely both GC alone and GC + tociluzimab were associated with survival (Table 6). The Kaplan Meier comparing all treatment groups is represented in Figure 2A (log rank test *P* < 0.001). Separate Kaplan Meier comparing each group and standard care are represented in Figure 2B (GC and standard of care, log rank *P* = 0.002), and Figure 2C (tocilizumab + GC and standard care, log rank *P* = 0.016), and Figure 2D (tocilizumab alone and standard care, log rank *P* = 0.061).

In order to adjust for time of GC administration, we employed a propensity score adjusted Cox proportional hazards analysis adjusting GC administration as a time dependent covariate, which revealed independent predictors of decreased survival were: increased age, male sex, and a requirement for vasopressors. GC use including those patients receiving GC alone and those receiving GC + tocilizimab was associated with survival. Conversely, the addition of GC as the time adjusted covariate was associated with a significant decrease in survival and negatively impacted the survival impact of GC treatment suggesting that later initiation of GC is associated with a negative impact on survival (Table 7). The analysis was repeated comparing all treatment groups which revealed the same independent predictors of decreased survival were the following: Increased age, male sex, and a requirement for vasopressors. The groups receiving GC alone and those receiving GC + tocilizumab were associated with survival (Table 8).

***Cox proportional hazards analysis adjusted for differences among groups***

Among treatment groups, there were significant differences in baseline characteristics observed on univariate analysis (Table 6). In order to adjust for these differences, we repeated the previous Cox proportional hazards analysis model incorporating SOFA score, baseline SCr, FiO2, history of coronary artery disease, and CRP at 24, and all previous variables analyzed on previous Cox models. The propensity score adjusted Cox proportional hazards model with GC as a time dependent covariate demonstrated that older age, higher SOFA score, and higher baseline SCr were associated with poor outcomes while the combination of tocilizumab and GC was associated with increased survival (Table 7).

**DISCUSSION**

During the first wave of the pandemic patients requiring admission to the ICU were associated with a mortality of 30%-70%[29-33]. The requirement for mechanical ventilation is associated with the highest mortality[30-32,34]. One observational study from Wuhan Du *et al*[30] reported that all 52 patients admitted to the ICU expired during the index hospitalization. In the present study, mortality was consistent with previously reported studies particularly, due to the large percentage of patients requiring mechanical ventilation[30-32,35]. Similarly, we demonstrate that male sex, advancing age, and requirements for vasopressor support were independent predictors of decreased survival[32,36]. Similar to experiences in Wuhan, patients not initially admitted to ICU had significant organ dysfunction with a median SOFA score of 3[30].

The geographical area that the hospitals in the current study services represent one of the largest Medicare populations in the country. Thus overall, the current study represents treatment in an older group of patients and patients requiring mechanical ventilation when compared to the RECOVERY trial and the Northwell COVID-19 treatment consortium[14,37]. The results of the current study demonstrating improved survival in patients receiving anti-inflammatory should be viewed with this context in mind.

A dysregulated immune response resulting in a hyper-inflammatory state is a hallmark of COVID-19 patients who develop severe progressive respiratory failure and multi-organ dysfunction[38]. A small percentage of these patients have clinical characteristics and laboratory parameters similar to macrophage activation syndrome or cytokine storm seen in H1N1 influenza and CAR-T therapy[39-42]. Although many pro-inflammatory cytokines are elevated in patients with severe COVID -19 infection, there is mounting evidence that increased pro-inflammatory cytokine signatures of IL-6 and TNF-α correlate with severity of disease and increased mortality[38,43,44]. Thus, from therapeutic standpoint therapies that inhibit the NFK-β pathway and IL-6 make GC and tocilizumab prime therapeutic candidates[37-38].

During the first wave of the pandemic, the use of anti-inflammatory therapy may have been predicted by understanding the pathophysiology of cytokine storms observed in CAR-T and in previous influenza viruses, experience in ARDS, and by some who believed the evidence supported the use of GC in viral pneumonia[22,45-47]. Long *et al*[48] reported improvement in mortality outcomes in 5327 patients with SARS associated with MERS in those patients receiving GC therapy. Likewise, Li *et al*[49] reported improved mortality outcomes in patients hospitalized with A(H1N1)pdm09 influenza[46,48-50]. In March 2020, Wu reported an observational study of 84 patients revealing reduced mortality risk in patients with ARDS risk receiving methylprednisone[50].

Prior to the RECOVERY trial, the use of GC in the treatment of severe COVID-19 was considered controversial and potentially harmful as treatment possibly could increase and prolong viral shedding. To some degree treatment with GC is still not without controversy[16,51]. Towards the end of the third wave, there has been increasing evidence from randomized controlled trials and observational studies that GC therapy improves survival in severe COVID-19, and the use of GC in low to moderate dosing is not associated with increased viral shedding[14,15,51,52]. To date, the use of anti-cytokine therapy mainly with anti-IL-6 treatment with tocilizumab has yielded mixed results[53-55].

In many infections, it is not the pathogen that determines the virulence of the disease. Instead, it is the host response to the pathogen that causes tissue injury, delayed healing, morbidity, and mortality. COVID-19 associated respiratory failure is a cehost response hyper-inflammatory pulmonary disease driven by macrophages and hyper-cytokinemia[54–56]. Of note, most patients with SARS-CoV-2 infection are mild or completely asymptomatic, with only a minority progressing to severe illness[54]. In the setting of mild or asymptomatic disease, there is an appropriate release of antiviral interferons, clearance of viral debris by phagocytosis, and a controlled innate immune response followed by the development of adaptive immunity[54,56,57]. However, there is an impaired release of interferons and an abnormal innate immune response associated with excessive hyper-inflammatory response in the small subset of patients progressing to severe disease[57]. Although SARS-CoV-2 viral cytopathic effect on the epithelial cells of the respiratory tract has been demonstrated, investigators have found it challenging to retrieve live virus during the severe symptomatic pulmonary phase of the disease despite clinical evidence of tissue injury and damage[58]. The positive response of anti-inflammatory and immunomodulatory agents in severe SARS-CoV-2 infection underscores the dysregulated hyper-inflammatory host response responsible for the tissue damage and virulence of severe COVID-19.

Although in the present study elevated body mass index did not significantly correlate with mortality, hyper-nutrition (sarcopenic obesity) is a known risk factor for developing severe COVID-19 disease and mortality[59]. Due to increased expression of the angiotensin converting enzyme-2 receptor, adipose tissue is a target for SARS-CoV-2 infection, adipose tissue function as an endocrine organ which results in a pro-inflammatory state, activation of NOD-, LRR-, and pyrin domain-containing protein 3 inflammasome and release of pro-inflammatory cytokines[60–63]. In addition, increase adipose tissue increases circulating TNF-α and IL-6[61]. Furthermore, obesity is associated with CD-4 T-cell exhaustion and decreases in anti-inflammatory cytokines IL-10 and IL-4[61,64,65]. Thus hyper-nutrition obesity sarcopenic patients are at higher risk for acquiring infection and developing the inflammatory immune dysregulation observed in severe COVID-19 disease[61,65].

Unfortunately, the current study did not investigate the presence gastrointestinal (GI) manifestation of severe COVID-19 disease. Further studies are needed to explore the possible organ crosstalk between the pulmonary and GI systems as the GI tract is both a driver of inflammation and a potential infectious source[66].

In the current study, we demonstrated the survival benefit of anti-inflammatory therapy employing several Cox proportional hazard models. Firstly, univariate analysis of therapy revealed survival benefit in all patients receiving GC treatment and tocilizumab + GC treatment while tocilizumab alone offered no survival benefit. Unadjusted multivariate analysis, propensity score adjusted Cox proportional hazard with and without GC use as a time-adjusted covariate supported survival benefits observed in the univariate analysis. Cox proportional hazards with GC therapy as a time dependent covariate suggest that earlier treatment with GC offers a greater survival benefit. After adjusting for differences among patient groups, combination therapy with tocilizumab + GC remained associated with increased patient survival. Overall combination therapy with tociluzimab + GC offered the greatest survival benefit.

The strengths of the current study are it represents a real world scenario in the treatment of critically ill patients in a predominantly older population with COVID-19 during the first wave of the pandemic when there was a paucity of randomized controlled evidence guiding therapy. Study limitations include the retrospective nature of the study and the difficulty in adjusting for confounding due to multiple interventions involved.

**CONCLUSION**

Anti-inflammatory therapy with GC and combination treatment with tocilizumab and GC improve survival in critically ill patients with COVID-19. Dual inhibition of the NFK-β therapy with GC and inhibition of the Il-6 pathway with tocilizumab may offer greater survival benefits. It is pertinent to note that monotherapy with tocilizumab alone was not associated with an increase in survival. Further prospective studies investigating combination anti-inflammatory therapy and timing of initiation of therapy are needed.

**ARTICLE HIGHLIGHTS**

***Research background***

Anti-inflammatory therapies have been the focus of treatment for severe hospitalized coronavirus disease 2019 (COVID-19) patients. Mixed literature has led to multiple approaches to providing these immune-modulating agents to calm the host response which has been shown to cause severe illness. Our study provides a retrospective evaluation of treatment provided to ICU-admitted COVID-19 patients and their outcomes.

***Research motivation***

Corticosteroids have clearly been the mainstay of treatment for hypoxic COVID-19 patients, but there has been debate on the best approach for additional anti-inflammatory therapies. Studies surrounding tocilizumab have previously shown mixed results complicated by a changing treatment regimen as we learned more about the disease process.

***Research objectives***

The objective of this evaluation was to evaluate treatment provided to severe COVID-19 patients early in the pandemic at our institution and provide additional guidance on any regimens which were associated with improvement in patient outcomes. What was clear after our assessment was that anti-inflammatory therapies using corticosteroids, potentially in combination with tocilizumab, could provide the best outcomes for our patients.

***Research methods***

Two hundred and sixty-one patients admitted to two community hospital intensive care units for severe COVID-19 were retrospectively analyzed for risk factors for mortality using propensity matched scoring.

***Research results***

Patient survival was associated with corticosteroid use, with or without tocilizumab. Timing of administration of corticosteroids was an important factor which determined patient outcomes with delays leading to decreased survival. No differences were found with use of anticoagulation, convalescent plasma, tocilizumab monotherapy, prone ventilation, hydroxychloroquine, azithromycin, or intravenous ascorbic acid use.

***Research conclusions***

Anti-inflammatory therapy with corticosteroids with or without tocilizumab was associated with the best outcomes in our cohort of severe COVID-19 patients.

***Research perspectives***

More trials are needed based on the appropriate dose, timing, and duration of corticosteroids in COVID-19. The benefit of tocilizumab and corticosteroids as combination treatment also needs to be explored further in randomized trials.

**ACKNOWLEDGEMENTS**

The authors would like to thank all of their colleagues at Community Medical Center and Monmouth Medical Center Southern Campus who have given their all during this pandemic. Their dedication to patient care has undoubtedly saved countless lives.

**REFERENCES**

1 **Lauer SA**, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* 2020; **172**: 577-582 [PMID: 32150748 DOI: 10.7326/M20-0504]

2 **Chen H**, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J, Yang H, Hou W, Zhang Y. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet* 2020; **395**: 809-815 [PMID: 32151335 DOI: 10.1016/S0140-6736(20)30360-3]

3 **World Health Organization**. WHO Director-General’s opening remarks at the media briefing on COVID-19. 2020 [cited 16 July 2020]. Available from: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-on-covid-19---11-march-2020

4 **World Health Organization**. Coronavirus disease 2019 (COVID-19) Situation Report. 2020 [cited 16 July 2020]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200716-covid-19-sitrep-178.pdf?sfvrsn=28ee165b\_2

5 **Li X**, Ma X. Acute respiratory failure in COVID-19: is it "typical" ARDS? *Crit Care* 2020; **24**: 198 [PMID: 32375845 DOI: 10.1186/s13054-020-02911-9]

6 **Ye Q**, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. *J Infect* 2020; **80**: 607-613 [PMID: 32283152 DOI: 10.1016/j.jinf.2020.03.037]

7 **Khan IH**, Savarimuthu S, Leung MST, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients. *J Vasc Surg* 2020; **72**: 799-804 [PMID: 32417304 DOI: 10.1016/j.jvs.2020.05.015]

8 **Merkler AE**, Parikh NS, Mir S, Gupta A, Kamel H, Lin E, Lantos J, Schenck EJ, Goyal P, Bruce SS, Kahan J, Lansdale KN, LeMoss NM, Murthy SB, Stieg PE, Fink ME, Iadecola C, Segal AZ, Campion TR Jr, Diaz I, Zhang C, Navi BB. Risk of Ischemic Stroke in Patients with Covid-19 *versus* Patients with Influenza. medRxiv 2020 [PMID: 32511527 DOI: 10.1101/2020.05.18.20105494]

9 **COVID-19 Treatment Guidelines Panel**. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2021 Feb 22. [cited 22 February 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/

10 **Wang M**, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020; **30**: 269-271 [PMID: 32020029 DOI: 10.1038/s41422-020-0282-0]

11 **Beigel JH**, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med* 2020; **383**: 1813-1826 [PMID: 32445440 DOI: 10.1056/NEJMoa2007764]

12 **Goldman JD**, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, Spinner CD, Galli M, Ahn MY, Nahass RG, Chen YS, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wei X, Gaggar A, Brainard DM, Towner WJ, Muñoz J, Mullane KM, Marty FM, Tashima KT, Diaz G, Subramanian A; GS-US-540-5773 Investigators. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. *N Engl J Med* 2020; **383**: 1827-1837 [PMID: 32459919 DOI: 10.1056/NEJMoa2015301]

13 **Spinner CD**, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. Effect of Remdesivir *vs* Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA* 2020; **324**: 1048-1057 [PMID: 32821939 DOI: 10.1001/jama.2020.16349]

14 **RECOVERY Collaborative Group**,Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med* 2021; **384**: 693-704 [PMID: 32678530 DOI: 10.1056/NEJMoa2021436]

15 **WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group**,Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, Dequin PF, Du B, Emberson J, Fisher D, Giraudeau B, Gordon AC, Granholm A, Green C, Haynes R, Heming N, Higgins JPT, Horby P, Jüni P, Landray MJ, Le Gouge A, Leclerc M, Lim WS, Machado FR, McArthur C, Meziani F, Møller MH, Perner A, Petersen MW, Savovic J, Tomazini B, Veiga VC, Webb S, Marshall JC. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. *JAMA* 2020; **324**: 1330-1341 [PMID: 32876694 DOI: 10.1001/jama.2020.17023]

16 **Jeronimo CMP**, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Safe IP, Borba MGS, Netto RLA, Maciel ABS, Neto JRS, Oliveira LB, Figueiredo EFG, Oliveira Dinelly KM, de Almeida Rodrigues MG, Brito M, Mourão MPG, Pivoto João GA, Hajjar LA, Bassat Q, Romero GAS, Naveca FG, Vasconcelos HL, de Araújo Tavares M, Brito-Sousa JD, Costa FTM, Nogueira ML, Baía-da-Silva DC, Xavier MS, Monteiro WM, Lacerda MVG; Metcovid Team. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. *Clin Infect Dis* 2021; **72**: e373-e381 [PMID: 32785710 DOI: 10.1093/cid/ciaa1177]

17 **Arabi YM**, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, Almotairi A, Al Khatib K, Alraddadi B, Shalhoub S, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Balkhy HH, Al Harthy A, Deeb AM, Al Mutairi H, Al-Dawood A, Merson L, Hayden FG, Fowler RA; Saudi Critical Care Trial Group. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. *Am J Respir Crit Care Med* 2018; **197**: 757-767 [PMID: 29161116 DOI: 10.1164/rccm.201706-1172OC]

18 **Stockman LJ**, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006; **3**: e343 [PMID: 16968120 DOI: 10.1371/journal.pmed.0030343]

19 **Liu J**, Zhang S, Dong X, Li Z, Xu Q, Feng H, Cai J, Huang S, Guo J, Zhang L, Chen Y, Zhu W, Du H, Liu Y, Wang T, Chen L, Wen Z, Annane D, Qu J, Chen D. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. *J Clin Invest* 2020; **130**: 6417-6428 [PMID: 33141117 DOI: 10.1172/JCI140617]

20 **Aziz M**, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. *J Med Virol* 2020; **92**: 2283-2285 [PMID: 32343429 DOI: 10.1002/jmv.25948]

21 **Zhu J**, Pang J, Ji P, Zhong Z, Li H, Li B, Zhang J. Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. *J Med Virol* 2021; **93**: 35-37 [PMID: 32470146 DOI: 10.1002/jmv.26085]

22 **Salvarani C**, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C, Ballerini PF, Sciascia R, Zammarchi L, Para O, Scotton PG, Inojosa WO, Ravagnani V, Salerno ND, Sainaghi PP, Brignone A, Codeluppi M, Teopompi E, Milesi M, Bertomoro P, Claudio N, Salio M, Falcone M, Cenderello G, Donghi L, Del Bono V, Colombelli PL, Angheben A, Passaro A, Secondo G, Pascale R, Piazza I, Facciolongo N, Costantini M; RCT-TCZ-COVID-19 Study Group. Effect of Tocilizumab *vs* Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. *JAMA Intern Med* 2021; **181**: 24-31 [PMID: 33080005 DOI: 10.1001/jamainternmed.2020.6615]

23 **Stone JH**, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen YD, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Yinh JM, Bowman KA, Meyerowitz E, Zafar A, Drobni ZD, Bolster MB, Kohler M, D'Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. *N Engl J Med* 2020; **383**: 2333-2344 [PMID: 33085857 DOI: 10.1056/NEJMoa2028836]

24 **Rosas IO**, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, Skiest D, Aziz MS, Cooper N, Douglas IS, Savic S, Youngstein T, Del Sorbo L, Cubillo Gracian A, De La Zerda DJ, Ustianowski A, Bao M, Dimonaco S, Graham E, Matharu B, Spotswood H, Tsai L, Malhotra A. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. *N Engl J Med* 2021; **384**: 1503-1516 [PMID: 33631066 DOI: 10.1056/NEJMoa2028700]

25 **Hermine O**, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of Tocilizumab *vs* Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. *JAMA Intern Med* 2021; **181**: 32-40 [PMID: 33080017 DOI: 10.1001/jamainternmed.2020.6820]

26 **REMAP-CAP Investigators**, Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. *N Engl J Med* 2021; **384**: 1491-1502 [PMID: 33631065 DOI: 10.1056/NEJMoa2100433]

27 **Horby PW,** Pessoa-Amorim G, Peto L, *et al* Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. 2021 Preprint. Available from: medRxiv [DOI: 10.1101/2021.02.11.21249258]

28 **Sawhney S**, Fluck N, Fraser SD, Marks A, Prescott GJ, Roderick PJ, Black C. KDIGO-based acute kidney injury criteria operate differently in hospitals and the community-findings from a large population cohort. *Nephrol Dial Transplant* 2016; **31**: 922-929 [PMID: 27190340 DOI: 10.1093/ndt/gfw052]

29 **Wu Z**, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020; **323**: 1239-1242 [PMID: 32091533 DOI: 10.1001/jama.2020.2648]

30 **Du RH**, Liu LM, Yin W, Wang W, Guan LL, Yuan ML, Li YL, Hu Y, Li XY, Sun B, Peng P, Shi HZ. Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China. *Ann Am Thorac Soc* 2020; **17**: 839-846 [PMID: 32255382 DOI: 10.1513/AnnalsATS.202003-225OC]

31 **Wu C**, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020; **180**: 934-943 [PMID: 32167524 DOI: 10.1001/jamainternmed.2020.0994]

32 **Yang X**, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; **8**: 475-481 [PMID: 32105632 DOI: 10.1016/S2213-2600(20)30079-5]

33 **Ubaldo OGV**, Palo JEM, Cinco JEL. COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines. *Crit Care Res Pract* 2021; **2021**: 7510306 [PMID: 33604085 DOI: 10.1155/2021/7510306]

34 **King CS**, Sahjwani D, Brown AW, Feroz S, Cameron P, Osborn E, Desai M, Djurkovic S, Kasarabada A, Hinerman R, Lantry J, Shlobin OA, Ahmad K, Khangoora V, Aryal S, Collins AC, Speir A, Nathan S. Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. *PLoS One* 2020; **15**: e0242651 [PMID: 33227024 DOI: 10.1371/journal.pone.0242651]

35 **El-Solh AA**, Meduri UG, Lawson Y, Carter M, Mergenhagen KA. Clinical Course and Outcome of COVID-19 Acute Respiratory Distress Syndrome: Data From a National Repository. *J Intensive Care Med* 2021; **36**: 664-672 [PMID: 33685275 DOI: 10.1177/0885066621994476]

36 **Zhou F**, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**: 1054-1062 [PMID: 32171076 DOI: 10.1016/S0140-6736(20)30566-3]

37 **Narain S**, Stefanov DG, Chau AS, Weber AG, Marder G, Kaplan B, Malhotra P, Bloom O, Liu A, Lesser ML, Hajizadeh N; Northwell COVID-19 Research Consortium. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm. *Chest* 2021; **159**: 933-948 [PMID: 33075378 DOI: 10.1016/j.chest.2020.09.275]

38 **Darif D**, Hammi I, Kihel A, El Idrissi Saik I, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? *Microb Pathog* 2021; **153**: 104799 [PMID: 33609650 DOI: 10.1016/j.micpath.2021.104799]

39 **Tang L**, Yin Z, Hu Y, Mei H. Controlling Cytokine Storm Is Vital in COVID-19. *Front Immunol* 2020; **11**: 570993 [PMID: 33329533 DOI: 10.3389/fimmu.2020.570993]

40 **Soy M**, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. *Clin Rheumatol* 2020; **39**: 2085-2094 [PMID: 32474885 DOI: 10.1007/s10067-020-05190-5]

41 **Dholaria BR**, Bachmeier CA, Locke F. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. *BioDrugs* 2019; **33**: 45-60 [PMID: 30560413 DOI: 10.1007/s40259-018-0324-z]

42 **Ryabkova VA**, Churilov LP, Shoenfeld Y. Influenza infection, SARS, MERS and COVID-19: Cytokine storm - The common denominator and the lessons to be learned. *Clin Immunol* 2021; **223**: 108652 [PMID: 33333256 DOI: 10.1016/j.clim.2020.108652]

43 **Del Valle DM**, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, Marron TU, Xie H, Patel M, Tuballes K, Van Oekelen O, Rahman A, Kovatch P, Aberg JA, Schadt E, Jagannath S, Mazumdar M, Charney AW, Firpo-Betancourt A, Mendu DR, Jhang J, Reich D, Sigel K, Cordon-Cardo C, Feldmann M, Parekh S, Merad M, Gnjatic S. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020; **26**: 1636-1643 [PMID: 32839624 DOI: 10.1038/s41591-020-1051-9]

44 **Burke H**, Freeman A, Cellura DC, Stuart BL, Brendish NJ, Poole S, Borca F, Phan HTT, Sheard N, Williams S, Spalluto CM, Staples KJ, Clark TW, Wilkinson TMA; REACT COVID investigators. Inflammatory phenotyping predicts clinical outcome in COVID-19. *Respir Res* 2020; **21**: 245 [PMID: 32962703 DOI: 10.1186/s12931-020-01511-z]

45 **Antwi-Amoabeng D**, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. *J Med Virol* 2020; **92**: 2516-2522 [PMID: 32436994 DOI: 10.1002/jmv.26038]

46 **Villar J**, Confalonieri M, Pastores SM, Meduri GU. Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019. *Crit Care Explor* 2020; **2**: e0111 [PMID: 32426753 DOI: 10.1097/CCE.0000000000000111]

47 **Meduri GU**, Bridges L, Shih MC, Marik PE, Siemieniuk RAC, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. *Intensive Care Med* 2016; **42**: 829-840 [PMID: 26508525 DOI: 10.1007/s00134-015-4095-4]

48 **Long Y,** Xu Y, Wang B, Zhang L, Jia D, Xue F, Duan G, He J, Xia J, Xu D. Clinical recomme-ndations from an observational study on MERS: Glucocorticoids was benefit in treating SARS patients. *Int J Clin Exp Med* 2016; **9**: 8865-8873

49 **Li H**, Yang SG, Gu L, Zhang Y, Yan XX, Liang ZA, Zhang W, Jia HY, Chen W, Liu M, Yu KJ, Xue CX, Hu K, Zou Q, Li LJ, Cao B, Wang C; National Influenza A(H1N1)pdm09 Clinical Investigation Group of China. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. *Influenza Other Respir Viruses* 2017; **11**: 345-354 [PMID: 28464462 DOI: 10.1111/irv.12456]

50 **Wu C**, Hou D, Du C, Cai Y, Zheng J, Xu J, Chen X, Chen C, Hu X, Zhang Y, Song J, Wang L, Chao YC, Feng Y, Xiong W, Chen D, Zhong M, Hu J, Jiang J, Bai C, Zhou X, Xu J, Song Y, Gong F. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. *Crit Care* 2020; **24**: 643 [PMID: 33172477 DOI: 10.1186/s13054-020-03340-4]

51 **Cano EJ**, Fonseca Fuentes X, Corsini Campioli C, O'Horo JC, Abu Saleh O, Odeyemi Y, Yadav H, Temesgen Z. Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes: Systematic Review and Meta-analysis. *Chest* 2021; **159**: 1019-1040 [PMID: 33129791 DOI: 10.1016/j.chest.2020.10.054]

52 **Salton F**, Confalonieri P, Meduri GU, Santus P, Harari S, Scala R, Lanini S, Vertui V, Oggionni T, Caminati A, Patruno V, Tamburrini M, Scartabellati A, Parati M, Villani M, Radovanovic D, Tomassetti S, Ravaglia C, Poletti V, Vianello A, Gaccione AT, Guidelli L, Raccanelli R, Lucernoni P, Lacedonia D, Foschino Barbaro MP, Centanni S, Mondoni M, Davì M, Fantin A, Cao X, Torelli L, Zucchetto A, Montico M, Casarin A, Romagnoli M, Gasparini S, Bonifazi M, D'Agaro P, Marcello A, Licastro D, Ruaro B, Volpe MC, Umberger R, Confalonieri M. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia. *Open Forum Infect Dis* 2020; **7**: ofaa421 [PMID: 33072814 DOI: 10.1093/ofid/ofaa421]

53 **Casadevall A**, Pirofski LA. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. *Infect Immun* 1999; **67**: 3703-3713 [PMID: 10417127 DOI: 10.1128/IAI.67.8.3703-3713.1999]

54 **Azkur AK**, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, O'Mahony L, Gao Y, Nadeau K, Akdis CA. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. *Allergy* 2020; **75**: 1564-1581 [PMID: 32396996 DOI: 10.1111/all.14364]

55 **Pasrija R**, Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. *Int Immunopharmacol* 2021; **90**: 107225 [PMID: 33302033 DOI: 10.1016/j.intimp.2020.107225]

56 **Shah VK**, Firmal P, Alam A, Ganguly D, Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. *Front Immunol* 2020; **11**: 1949 [PMID: 32849654 DOI: 10.3389/fimmu.2020.01949]

57 **Blanco-Melo D**, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, Jordan TX, Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* 2020; **181**: 1036-1045.e9 [PMID: 32416070 DOI: 10.1016/j.cell.2020.04.026]

58 **Young BE**, Ong SWX, Ng LFP, Anderson DE, Chia WN, Chia PY, Ang LW, Mak TM, Kalimuddin S, Chai LYA, Pada S, Tan SY, Sun L, Parthasarathy P, Fong SW, Chan YH, Tan CW, Lee B, Rötzschke O, Ding Y, Tambyah P, Low JGH, Cui L, Barkham T, Lin RTP, Leo YS, Renia L, Wang LF, Lye DC; Singapore 2019 Novel Coronavirus Outbreak Research team. Viral dynamics and immune correlates of COVID-19 disease severity. *Clin Infect Dis* 2020 [PMID: 32856707 DOI: 10.1093/cid/ciaa1280]

59 **Docherty AB**, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG; ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020; **369**: m1985 [PMID: 32444460 DOI: 10.1136/bmj.m1985]

60 **Al Heialy S**, Hachim MY, Senok A, Gaudet M, Abou Tayoun A, Hamoudi R, Alsheikh-Ali A, Hamid Q. Regulation of Angiotensin- Converting Enzyme 2 in Obesity: Implications for COVID-19. *Front Physiol* 2020; **11**: 555039 [PMID: 33071815 DOI: 10.3389/fphys.2020.555039]

61 **Finelli C**. Obesity, COVID-19 and immunotherapy: the complex relationship!. *Immunotherapy* 2020; **12**: 1105-1109 [PMID: 32677493 DOI: 10.2217/imt-2020-0178]

62 **López-Reyes A**, Martinez-Armenta C, Espinosa-Velázquez R, Vázquez-Cárdenas P, Cruz-Ramos M, Palacios-Gonzalez B, Gomez-Quiroz LE, Martínez-Nava GA. NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19. *Front Immunol* 2020; **11**: 570251 [PMID: 33193349 DOI: 10.3389/fimmu.2020.570251]

63 **Huang Y**, Lu Y, Huang YM, Wang M, Ling W, Sui Y, Zhao HL. Obesity in patients with COVID-19: a systematic review and meta-analysis. *Metabolism* 2020; **113**: 154378 [PMID: 33002478 DOI: 10.1016/j.metabol.2020.154378]

64 **AbdelMassih AF**, Fouda R, Kamel A, Mishriky F, Ismail HA, El Qadi L, Malak L, Mohamed M, Arsanyous M, Hazem M, El-Husseiny M, Ashraf M, Hafez N, AlShehry N, El-Husseiny N, AbdelRaouf N, Shebl N, Hafez N, Youssef N, Afdal P, Hozaien R, Menshawey R, Saeed R, Yasser R, Hesham S, Zakarriah W, Khattab S, Elammary Y, Ye J. Single cell sequencing unraveling genetic basis of severe COVID19 in obesity. *Obes Med* 2020; **20**: 100303 [PMID: 32995660 DOI: 10.1016/j.obmed.2020.100303]

65 **Briguglio M**, Pregliasco FE, Lombardi G, Perazzo P, Banfi G. The Malnutritional Status of the Host as a Virulence Factor for New Coronavirus SARS-CoV-2. *Front Med (Lausanne)* 2020; **7**: 146 [PMID: 32391367 DOI: 10.3389/fmed.2020.00146]

66 **Troisi J**, Venutolo G, Pujolassos Tanyà M, Delli Carri M, Landolfi A, Fasano A. COVID-19 and the gastrointestinal tract: Source of infection or merely a target of the inflammatory process following SARS-CoV-2 infection? *World J Gastroenterol* 2021; **27**: 1406-1418 [PMID: 33911464 DOI: 10.3748/wjg.v27.i14.1406]

**Footnotes**

**Institutional review board statement:** The study was approved by the Community Medical Center Institutional Review Board (IRB # 20-005).

**Informed consent statement:** Informed consent was waived by the Community Medical Center Institutional Review Board as the study was deemed minimal risk to participants due to its retrospective nature and de-identified results.

**Conflict-of-interest statement:** None of the listed authors have any conflicts of interest to disclose.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE statement, and the manuscript was prepared and revised according to the STROBE statement.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** April 21, 2021

**First decision:** June 17, 2021

**Article in press:** August 4, 2021

**Specialty type:** Critical care medicine

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Yu L **S-Editor:** Liu M **L-Editor:** A **P-Editor:** Wang LYT

**Figure Legends**



**Figure 1 Kaplan Meier survival curve demonstrating increased survival in all patients who received glucocorticoid (red line) *vs* no** **glucocorticoid therapy (black line) log-rank test *P* < 0.001.**



**Figure 2 Kaplan Meier survival curve.** A: Kaplan Meier survival curve demonstrating increased survival differences in groups receiving tocilizimab + glucocorticoid (GC) (red line), GC alone (black line), tocilizumab alone (green line), and standard treatment (blue line), log rank test with Bonferroni adjustment, *P* < 0.001; B: Kaplan Meier survival curve comparing groups GC alone (black line), and standard treatment (red line) log rank test, *P* < 0.001; C: Kaplan Meier survival curve comparing groups tocilizumab + GC (black line), and standard treatment (red line) log rank test, *P* = 0.016; D: Kaplan Meier survival curve comparing groups tocilizumab (black line), and standard treatment (red line) log rank test, *P* = 0.062.

**Table 1 Coronavirus disease 2019 patients admitted to intensive care unit characteristics of survivors and non-survivors, *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Non-survivor (*n* = 167) | Survivor (*n* = 94) | *P* value | OR | 95%CI |
| Age  | 71 (61, 82) | 61 (62, 78) | 0.011 |  |  |
| Race (Caucasian) | 89 (75) | 40 (56) | 0.007 | 2.37 | 1.27-4.40 |
| BMI | 29 (23, 34) | 28 (24, 32) | 0.49 |  |  |
| Sex (male) | 75 (70) | 83 (53) | 0.01 | 0.49 | 0.29-0.84 |
| Diabetes | 31 (29) | 53 (34) | 0.3 | 1.26 | 0.75-2.2 |
| CHF | 13 (12) | 21 (14) | 0.7 | 1.1 | 0.66 – 2.4 |
| CAD | 24 (29) | 41 (27) | 0.41 | 1.2 | 0.7-2.2 |
| COPD | 38 (23) | 23 (30) | 0.75 | 0.9 | 0.5-1.6 |
| CKD | 11 (10) | 21 (17) | 0.1 | 1.85 | 0.87-3.83 |
| HTN | 54 (51) | 91 (59) | 0.16 | 1.4 | 0.86-2.3 |
| AKI | 87 (52) | 30 (32) | 0.002 | 2.3 | 1.21-2.5 |
| Mechanical ventilation | 134 (80) | 44 (47) | < 0.001 | 4.7 | 2.7-8.3 |
| Hemodialysis | 29 (18) | 10 (11) | 0.13 | 1.8 | 0.3-3.9 |
| Neutrophils × 109/L | 7.3 (4, 10) | 7.8 (5.1, 13) | 0.97 |  |  |
| Lymphocytes | 0.7 (0.5, 1.2) | 0.9 (0.6, 1.6) | 0.011 |  |  |
| Neutrophil/lymphocyte | 10 (6, 18) | 7.5 (4, 14) | 0.017 |  |  |
| SCr (mg/dL) | 1.2 (0.9, 1.9) | 1.2 (0.8, 1.8) | 0.49 |  |  |
| Plts (× 109 /L) | 230 (162, 310) | 236 (182, 302) | 0.27 |  |  |
| Tbili (mg/dL) | 0.5 (0.4, 0.8) | 0.5 (0.4, 0.8) | 0.65 |  |  |
| SOFA admit | 5 (3, 9) | 4 (2, 6) | 0.095 |  |  |
| PaO2/FIO2 | 190 (76, 285) | 232 (123, 307) | 0.039 |  |  |
| PaO2 | 68 (52, 116) | 66 (48-112) | 0.083 |  |  |
| FIO2 | 1 (0.45, 1) | 1 (0.96, 1) | 0.12 |  |  |

OR: Odds ratio; CI: Confidence interval; CAD: Coronary artery disease; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; CHF: Congestive heart failure; AKI: Acute kidney injury; HD: Hemodialysis; tBili: Total bilirubin; Plts: Platelets INR: International normalized ratio. PaO2/FiO2: Partial pressure of oxygen/inspired concentration of oxygen ratio; SOFA: Sequential Organ Failure Assessment; BMI: Body mass index; SCr: Serum creatinine.

**Table 2 Pharmacologic and therapeutic interventions in coronavirus disease 2019 intensive care unit patients, *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Non-survivor (*n* = 167)** | **Survivor (*n* = 94)** | ***P* value** | **OR** | **95%CI** |
| GC (all patients)1 | 99 (59) | 68 (72) | 0.035 | 0.55 | 0.32-0.96 |
| Vasopressors | 124 (74) | 35 (37) | < 0.001 | 4.8 | 2.8-8.4 |
| IV Ascorbic acid | 100 (59) | 54 (57) | 0.7 | 1.1 | 0.66-1.84 |
| Hydroxychloroquine | 128 (78) | 69 (75) | 0.57 | 1.2 | 0.65-2.1 |
| Azithromycin | 65 (40) | 25 (26) | 0.06 | 1.69 | 0.97-2.9 |
| Heparin therapeutic dose | 80 (48) | 51 (54) | 0.32 | 0.77 | 0.46-1.3 |
| Heparin prophylaxis dose | 58 (35) | 32 (34) | 0.91 | 1.03 | 0.6-1.75 |
| Convalescent plasma | 44 (26) | 27 (29) | 0.68 | 0.88 | 0.5-1.56 |
| Remdesivir | 6 (3) | 0 (0) |  |  |  |
| Prone positioning | 52 (31) | 32 (35) | 0.91 | 1.03 | 0.6-1.75 |
| Tocilizumab | 20 (12) | 8 (8.5) | 0.55 | 1.28 | 0.56-2.9 |
| GC only | 44 (26) | 29 (30) | 0.47 | 0.8 | 0.48-1.4 |
| GC + tocilizumab | 55 (32) | 39 (40) | 0.16 | 0.68 | 0.4-1.15 |

1Treatment stratified as total patients receiving glucocorticoid (GC) therapy (GC alone and GC + tocilizumab).

GC: Glucocorticoid; OR: Odds ratio; CI: Confidence interval; IV: Intravenous.

**Table 3 Univariate Cox proportional hazards survival analysis of pharmacological and therapeutic interventions in coronavirus disease 2019 intensive care unit patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **B** | **SE** | ***P* value** | **HR** | **95%CI** |
| GC (all patients) | -0.84 | 0.16 | < 0.001 | 0.45 | 0.38-0.61 |
| Vasopressors | 0.039 | 35 | 0.027 | 1.4 | 1.05-2.1 |
| IV ascorbic acid | 0.1 | 0.15 | 0.49 | 1.1 | 0.91-1.5 |
| Hydroxychloroquine | -0.58 | 0.36 | 0.1 | 0.56 | 0.27-1.14 |
| Azithromycin | 0.25 | 28 | 0.39 | 1.3 | 0.72-2.3 |
| Heparin therapeutic dose | 0.15 | 0.35 | 0.67 | 1.16 | 0.51-2.31 |
| Heparin prophylaxis dose | -0.27 | 0.3 | 0.35 | 0.76 | 0.48-1.3 |
| Convalescent plasma | 0.29 | 1 | 0.77 | 1.3 | 0.72-9.8 |
| Remdesivir | 6 (3) | 0 |  |  |  |
| Prone positioning | 0.36 | 0.52 | 0.44 | 1.43 | 0.51-1.4 |
| Tocilizumab | -0.48 | 0.27 | 0.08 | 0.61 | 0.36-1.06 |
| GC only | -0.75 | 0.21 | 0.001 | 0.47 | 0.18-0.41 |
| GC + tocilizumab | -1.3 | 0.21 | <0.001 | 0.27 | 0.4-1.15 |

HR: Hazard ratio; CI: Confidence interval; GC: Glucocorticoids; IV: Intravenous.

**Table 4 Inflammatory markers in coronavirus disease 2019 survivors and non-survivors**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Non-survivors (*n* = 167)** | **Survivors (*n* = 94)** | ***P* value** |
| IL-6 day 1 (pg/mL) | 112 (70, 137) | 100 (70, 135) | 0.34 |
| IL-6 day 2  | 415 (139, 476) | 350 (78, 423) | 0.016 |
| D-dimer day 1 (ng/mL) | 1125 (647, 2434) | 991 (513, 2196) | 0.04 |
| D-dimer day 2 | 849 (604, 1210) | 1140 (646, 2263) | 0.03 |
| CRP day 1 (mg/L) | 117 (89, 159) | 113 (96, 149) | 0.9 |
| CRP day 2 | 107 (81, 154) | 117 (88, 167) | 0.62 |
| Ferritin day 1 (ng/mL) | 931 (593, 1367) | 960 (609, 1395) | 0.51 |
| Ferritin day 2 | 822 (447, 1432) | 1053 (712, 2057) | 0.05 |

IL-6: Interleukin 6, CRP: C-reactive protein.

**Table 5 Unadjusted Cox proportional hazards analysis of independent predictors of survival in intensive care unit patients with coronavirus disease 2019**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **B** | **SE** | ***P* value** | **HR** | **95%CI** |
| Age | 0.031 | 0.007 | < 0.001 | 1.032 | 1.02-1.05 |
| Sex (male) | 0.39 | 0.2 | 0.046 | 1.48 | 1.008-2.2 |
| Vasopressors | 0.485 | 0.2 | 0.016 | 1.62 | 1.095-2.4 |
| GC administration (all patients)1 | -0.61 | 0.19 | 0.002 | 0.54 | 0.37-0.79 |

1Treatment stratified as total patients receiving GC therapy (GC alone and GC + tocilizumab).

HR: Hazard ratio; CI: Confidence interval; GC: Glucocorticoids.

**Table 6 Propensity score adjusted Cox proportional hazards analysis of independent predictors of survival in intensive care unit patients with coronavirus disease 2019**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **B** | **SE** | ***P* value** | **HR** | **95%CI** |
| Age | 0.03 | 0.007 | < 0.001 | 1.031 | 1.02-1.05 |
| Sex (male) | 0.41 | 0.2 | 0.038 | 1.51 | 1.022-2.22 |
| Vasopressors | 0.47 | 0.23 |  0.019 | 1.6 | 1.081-2.37 |
| GC + Tocilizumab | -0.78 | 0.22 | 0.001 | 0.46 | 0.29-0.72 |
| GC only | -0.44 | 0.22 | 0.048 | 0.65 | 0.42-0.99 |

SE: Standard error; HR: Hazard ratio; CI: Confidence interval; GC: Glucocorticoids; IV: Intravenous.

**Table 7 Propensity score adjusted (glucocorticoids as a time-adjusted covariate) Cox proportional hazards analysis of independent predictors of survival in intensive care unit patients with coronavirus disease 2019**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **B** | **SE** | ***P* value** | **HR** | **95%CI** |
| Time adjusted GC | 2.5 | 1.01 | 0.014 | 12.9 | 1.06-87.5 |
| Age | 0.03 | 0.007 | < 0.001 | 1.03 | 1.01-1.04 |
| Sex (male) | 0.4 | 0.2 | 0.05 | 1.5 | 1-2.17 |
| Vasopressors | 0.51 | 0.2 |  0.01 | 1.66 | 1.12-2.4 |
| GC (all patients)1 | -2.94 | 1.01 | 0.004 | 0.05 | 0.007-0.36 |

1Treatment stratified as total patients receiving glucocorticoids (GC) therapy (GC alone and GC + tocilizumab).

SE: Standard error; HR: Hazard ratio; CI: Confidence interval; GC: Glucocorticoids.

**Table 8 Propensity score adjusted (glucocorticoids as a time adjusted covariate) Cox proportional hazards analysis of independent predictors of survival in intensive care unit patients with all treatment groups added into the model**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **B** | **SE** | ***P* value** | **HR** | **95%CI** |
| Time adjusted GC | 2.5 | 1.01 | 0.015 | 12 | 1.62-85 |
| Age | 0.03 | 0.007 | < 0.001 | 1.03 | 1.01-1.04 |
| Sex (male) | 0.4 | 0.2 | 0.04 | 1.5 | 1.01-2.2 |
| Vasopressors | 0.5 | 0.2 |  0.01 | 1.66 | 1.12-2.45 |
| GC + tocilizumab | -3.07 | 1.02 | 0.003 | 0.046 | 0.006-0.46 |
| GC (only) | -2.77 | 1.02 | 0.007 | 0.06 | 0.008-0.46 |

SE: Standard error; HR: Hazard ratio; CI: Confidence interval; GC: Glucocorticoids.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**